Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Chemotherapy Delay on Overall Survival for AML with I DH1/2 Mutations: A Study in Adult Chinese Patients

Blood (2015) 126 (23): 4905.

https://doi.org/10.1182/blood.V126.23.4905.4905

Published: 2015

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia

Qiu-Ling Ma, Jing-Han Wang, Yun-gui Wang, Chao Hu, Qi-Tian Mu, Meng-Xia Yu, Lei Wang, Dong-Mei Wang, Min Yang, Xiu-Feng Yin, Fei-Fei Chen, Sha-Sha Lu, Jian Chen, Zhi-Juan Zhu, Sai-Juan Chen, PhD, MD, Jie Jin, MD

Blood (2014) 124 (21): 5314.

https://doi.org/10.1182/blood.V124.21.5314.5314

Published: 2014

Journal Articles

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

Blood (2014) 124 (10): 1645–1654.

https://doi.org/10.1182/blood-2014-02-554204

Published: 2014

Includes: Supplemental data

Journal Articles

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Mamta Gupta, Ph.D, Guangzhen Hu, Linda E Wellik, Jing Jing Han, Mary Stenson, B.S, Ahmet Dogan, MD, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 632.

https://doi.org/10.1182/blood.V122.21.632.632

Published: 2013

Journal Articles

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

Mamta Gupta, Ph.D, Jing Jing Han, Mary Stenson, B.S, Linda E Wellik, Thomas E Witzig, MD

Blood (2013) 122 (21): 636.

https://doi.org/10.1182/blood.V122.21.636.636

Published: 2013

Journal Articles

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

Mamta Gupta, Ph.D, Matthew J. Maurer, MS, Mary Stenson, B.S, Linda E. Wellik, Jing Jing Han, Andrew L. Feldman, Thomas M. Habermann, MD, Thomas E. Witzig, MD

Blood (2013) 122 (21): 844.

https://doi.org/10.1182/blood.V122.21.844.844

Published: 2013

Journal Articles

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

Mamta Gupta, Matthew J. Maurer, Linda E. Wellik, Mark E. Law, Jing Jing Han, Nazan Ozsan, Ivana N. Micallef, Ahmet Dogan, Thomas E. Witzig

Blood (2012) 120 (22): 4400–4406.

https://doi.org/10.1182/blood-2012-05-428466

Published: 2012

Includes: Supplemental data

Journal Articles

Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.

Mamta Gupta, Ph.D, Guangzhen Hu, Steven Offer, Matthew J Maurer, MS, Linda Wellik, Jing Jing Han, Ahmet Dogan, MD, PhD, Robert B. Diasio, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2655.

https://doi.org/10.1182/blood.V120.21.2655.2655

Published: 2012

Journal Articles

Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia

Blood (2012) 120 (21): 1433.

https://doi.org/10.1182/blood.V120.21.1433.1433

Published: 2012

Journal Articles

Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP

Mamta Gupta, Ph.D, Matthew J Maurer, MS, Linda Wellik, Mark E Law, Jing Jing Han, Ivana N. Micallef, MD, Ahmet Dogan, MD, PhD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 1575.

https://doi.org/10.1182/blood.V120.21.1575.1575

Published: 2012

Journal Articles

Prognostic Significance of Minimal Residual Disease in Adult Patients with B-Lineage Acute Lymphoblastic Leukemia by 8-Color Flow Cytometry

Xiang-Qin Weng, Yang Shen, MD, Yan Sheng, Bing Chen, PhD, Jing-han Wang, PhD, Jun-ming Li, MD, Yong-Mei Zhu, Sai-Juan Chen, PhD

Blood (2012) 120 (21): 4789.

https://doi.org/10.1182/blood.V120.21.4789.4789

Published: 2012

Journal Articles

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Mamta Gupta, Jing Jing Han, Mary Stenson, Matthew Maurer, Linda Wellik, Guangzhen Hu, Steve Ziesmer, Ahmet Dogan, Thomas E. Witzig

Blood (2012) 119 (12): 2844–2853.

https://doi.org/10.1182/blood-2011-10-388538

Published: 2012

Includes: Supplemental data

Journal Articles

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Mamta Gupta, Andrea E. Wahner Hendrickson, Seong Seok Yun, Jing Jing Han, Paula A. Schneider, Brian D. Koh, Mary J. Stenson, Linda E. Wellik, Jennifer C. Shing, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Sharon Barr, Thomas E. Witzig, Scott H. Kaufmann

Blood (2012) 119 (2): 476–487.

https://doi.org/10.1182/blood-2011-04-346601

Published: 2012

Includes: Supplemental data

Journal Articles

Microarray and Proteomic Analysis of Myeloproliferative Neoplasms,

Vladan P Cokic, MD, PhD, Pascal Mossuz, MD, PhD, Jing Han, PhD, Milos Diklic, Mirela Budec, MD, PhD, Dijana Sefer, MD, MSc, Danijela Lekovic, MD, Darko Antic, MD, PhD, Tijana Brekovic, Sonja Mojsilovic, MSc, Raj K Puri, MD, PhD, Constance Tom Noguchi, PhD, Alan N Schechter, MD

Blood (2011) 118 (21): 3856.

https://doi.org/10.1182/blood.V118.21.3856.3856

Published: 2011

Journal Articles

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

Mamta Gupta, Ph.D, Mary Stenson, Jing Jing Han, Matthew J Maurer, MS, Linda Wellik, Steven C. Ziesmer, Ahmet Dogan, Thomas E. Witzig, MD

Blood (2011) 118 (21): 960.

https://doi.org/10.1182/blood.V118.21.960.960

Published: 2011

Journal Articles

HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

Mamta Gupta, Ph.D, Jing Jing Han, Mary Stenson, Linda Wellik, Thomas E. Witzig, MD

Blood (2010) 116 (21): 115.

https://doi.org/10.1182/blood.V116.21.115.115

Published: 2010

Journal Articles

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

Mamta Gupta, Ph.D, Andrea Wahner Hendrickson, Jing Jing Han, Mary Stenson, Linda Wellik, Sharon Barr, Scott H. Kaufmann, MD, PhD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 772.

https://doi.org/10.1182/blood.V116.21.772.772

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Chemotherapy Delay on Overall Survival for AML with I DH1/2 Mutations: A Study in Adult Chinese Patients

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP

Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.

Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia

Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP

Prognostic Significance of Minimal Residual Disease in Adult Patients with B-Lineage Acute Lymphoblastic Leukemia by 8-Color Flow Cytometry

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Microarray and Proteomic Analysis of Myeloproliferative Neoplasms,

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only